Announcement PDF (ASX:EMD) Creating tomorrow’s therapies from today’s patient stories Company Update | July 2023 DISCLAIMER This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation. Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Emyria. To the maximum extent permitted by law, Emyria and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation. An investment in Emyria securities should be considered speculative and is subject to investment and other known and unknown risks, some of which are beyond the control of Emyria. Emyria does not guarantee any rate of return or the absolute or relative investment performance of Emyria securities. The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions. This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Emyria and certain of the plans and objectives of Emyria with respect to these items. These forward-looking statements are not historical facts but rather are based on Emyria's current expectations, estimates and projections about the industry in which Emyria operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Emyria, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Emyria cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Emyria only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Emyria will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority. Presentation release authorised by Michael Winlo, CEO and Managing Director Emyria 2023 2 EMYRIA’S CAPITAL STRUCTURE Listed on ASX Feb, 2020 Tenmile 7.8% KEY METRICS VALUE Market Capitalisation ~A$42M Last reported cash (at 31 Mar 2023) A$2.2M + R&D $917k (April) + Placement $2.5M (April) Other Holdings Directors 27% Top 50 67.2% >3,000 shareholders OUR GLOBAL VISION | INNOVATIVE CARE & THERAPY DEVELOPMENT Our robust CARE DELIVERY & services, brought to you by , and are built on a triad of excellence: CARE DELIVERY Achieving transformative patient outcomes Generating sustainable revenue streams Gathering valuable REAL-WORLD DATA This virtuous cycle fuels our THERAPY DEVELOPMENT REAL WORLD DATA Creating Ultra-Pure Cannabinoids Exploring MDMA analogues Pioneering psychedelic-assisted therapies THERAPY DEVELOPMENT Together, these pillars embody Emyria's commitment to advancing MENTAL HEALTH CARE THE PROBLEM | THE RISING COST & BURDEN OF MENTAL HEALTH CARE The Mental Health Burden in Australia 1 in 5 adults and 1 in 7 young people experienced a mental health disorder in the previous 12 months 1 4.7 million people (18% of Australians) filled a mental health-related prescription in 2021–22 1 $11.6 billion was spent on mental health services in 2020-21, around 7.3% of the total government health expenditure 1 BUT… 1 in 3 psychologists have closed books! 2 In 2019, US spending on mental health treatments surpassed $225B 3 SOURCE: 1. https://www.aihw.gov.au/mental-health 2. https://psychology.org.au/for-members/news-and-updates/news/2022/australians-need-psychological-help-more-than-ever 3. https://www.behavr.com/mental-wellness Emyria 2023 5 THE GAP | SAFE, EFFECTIVE, DURABLE & AFFORDABLE TREATMENTS Psychedelic-assisted therapy shows remarkable promise for addressing this gap 67% of participants in the MDMA group no longer met criteria for PTSD two months after the sessions. (c/w 32% of participants in the placebo group) 1 SOURCE: 1. Mitchell, J.M., Bogenschutz, M., Lilienstein, A. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 27, 1025–1033 (2021) Emyria 2023 6 REGULATORS ARE CHANGING THEIR STANCE ON MDMA & PSILOCYBIN EXCITING REGULATORY SHIFT In a world first, Australia has officially recognised MDMA and psilocybin as controlled medicines from July 1st, 2023. SOURCE: 1. https://www.tga.gov.au/products/unapproved-therapeutic-goods/mdma-and-psilocybin Emyria 2023 7 GIVING AUSTRALIA AT LEAST A 1 YEAR HEAD START ON REST OF WORLD 2023 TIMELINE Q3 Australia Controlled medicines USA 1 2024 Q4 NDA submission Q1 Q2 Q3 Q4 DEA decision? Launch? Patients can be treated Emyria 2023 SOURCE: 1. Presentation MAPS Psychedelic Symposium, Denver, CO, June 2023 8 HOWEVER… MEDICINES ONLY AVAILABLE VIA AUTHORISED PSYCHIATRISTS FOR SPECIFIC CONDITIONS OR Clinical Trials “For approval to prescribe, psychiatrists will need to demonstrate appropriate training, patient selection, evidence-based treatment protocols and patient monitoring. Further, ongoing psychotherapeutic support remains an essential component of the psychedelic treatment model.” -RANZCP (College of Psychiatrists) Emyria 2023 SOURCE: 1. https://www.ranzcp.org/clinical-guidelines-publications/clinical-guidelines-publications-library/therapeutic-use-of-mdma-for-ptsd-and-psilocybin-for-treatment-resistant-depression 9 …AND DELIVERY COSTS ARE HIGH DUE TO INTENSIVE THERAPY Example: MDMA-assisted therapy protocol PRE-TREATMENT PERIOD 2-12 weeks TREATMENT PERIOD (12 weeks) FOLLOW-UP PERIOD (12 months from last Treatment Session) PREPARATION (1-8 weeks) TREATMENT CYCLE 1 (4 weeks) TREATMENT CYCLE 2 (4 weeks) TREATMENT CYCLE 3 (4 weeks) Clinic visit(s) Preparatory Session 1 (1.5 hrs) Treatment Session 1 (8 hrs) Treatment Session 2 (8 hrs) Treatment Session 3 (8 hrs) Integration Session 1.1 (1.5 hrs) Integration Session 2.1 (1.5 hrs) Integration Session 3.1 (1.5 hrs) Integration Session 1.2 (1.5 hrs) Integration Session 2.2 (1.5 hrs) Integration Session 3.2 (1.5 hrs) Integration Session 1.3 (2 hrs) Integration Session 2.3 (2 hrs) Integration Session 3.3 (2 hrs) External lab visit(s) Medication Taper SCREENING (1-4 weeks) Preparatory Session 2 (Baseline) (2 hrs) 3-month Follow-Up (2 hrs) 6-month Follow-Up (2 hrs) 12-month Follow-Up (2 hrs) CURRENT PER PATIENT COST FOR 3 ROUNDS OF TREATMENT IS ~$25k Emyria 2023 10 How are we going to deliver psychedelic-assisted therapy & how will patients afford them? ? Very few clinical services are currently capable of delivering these therapies. & We need more evidence. WHAT’S NEEDED FOR AFFORDABLE PSYCHEDELIC-ASSISTED THERAPY? (1) THRIVING CLINICAL SERVICE A vibrant, patient-centric clinical service is crucial for integrating these therapies and gathering data. We need to build the necessary infrastructure and support systems to incorporate innovative treatments while upholding the highest standards of care. Emyria 2023 13 WHAT’S NEEDED FOR AFFORDABLE PSYCHEDELIC-ASSISTED THERAPY? (1) THRIVING CLINICAL SERVICE A vibrant, patient-centric clinical service is crucial for integrating these therapies and gathering data. We need to build the necessary infrastructure and support systems to incorporate innovative treatments while upholding the highest standards of care. (2) SKILL WITH EMERGING THERAPIES & The unique and complex nature of psychedelic-assisted therapies demands specific expertise and understanding. Mastery in managing these intricate treatments—from careful patient selection, to the nuances of therapeutic guidance during sessions, to integration afterwards—is an absolute necessity. Emyria 2023 14 WHAT’S NEEDED FOR AFFORDABLE PSYCHEDELIC-ASSISTED THERAPY? (1) THRIVING CLINICAL SERVICE A vibrant, patient-centric clinical service is crucial for integrating these therapies and gathering data. We need to build the necessary infrastructure and support systems to incorporate innovative treatments while upholding the highest standards of care. (3) ROBUST CLINICAL DATA (2) SKILL WITH EMERGING THERAPIES & The unique and complex nature of psychedelic-assisted therapies demands specific expertise and understanding. Mastery in managing these intricate treatments—from careful patient selection, to the nuances of therapeutic guidance during sessions, to integration afterwards—is an absolute necessity. & To help navigate and solve intricate puzzles relating to dosage, patient response, safety protocols, long-term outcomes and cost benefits we require high-quality, robust data. Establishing a solid scientific foundation is crucial to instill confidence among professionals, patients, and regulators. Emyria 2023 15 Emyria has done this before…. OUR CLINICAL SERVICE EVOLUTION Emyria commences drug development programs: novel Ultra-Pure CBD formulation + proprietary MDMA analogues 3 THC & CBD legalised medicines in Australia 1 Dec 2016 2018 2020 ASX Emyria establishes specialist clinics (Emerald Clinics) and treats first patients with THC and CBD (~10,000 patients treated since 2) SOURCES: 1. https://www.tga.gov.au/news/news/final-decision-scheduling-cannabis-and-tetrahydrocannabinols-frequently-asked-questions#decision 2. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2804653 3. https://emyria.com/development-programs/ 4. See ASX release 22 Nov 2021 5. See ASX release 18 Oct 2023 Emyria 2023 6. See ASX release 04 April 2023 7. https://www.tga.gov.au/products/unapproved-therapeutic-goods/mdma-and-psilocybin 17 OUR ADVANTAGES | A PROVEN TRACK RECORD A data-centric clinical service working with newly rescheduled treatments like THC & CBD to monitor & care for patients when “nothing else has worked” Emerald Cli ● GP-led clinical service ● ~10,000+ patients ● 40+ clinical conditions ● Cannabinoid-based medicine specialists ● World’s largest data registry on cannabinoid-based therapies and outcomes 1 ● Leveraging Foundry 2 SOURCES: 1. Arkell TR, et al. Assessment of Medical Cannabis and Health-Related Quality of Life. JAMA Netw Open. 2023;6(5):e2312522. doi:10.1001/jamanetworkopen.2023.12522 2. See ASX 22 Oct 2021 Emyria 2023 18 OUR ADVANTAGES | ROBUST DATA CAPTURE & ANALYSIS CAPABILITIES We are experienced in tracking clinical outcomes & personalising care % of patients with “moderate” to “severe” ANXIETY, DEPRESSION, STRESS TOP 10 indications: ANXIETY 1 DEPRESSION 1 STRESS 1 INSOMNIA 2 Chronic non-cancer pain 73 52 39 60 Insomnia 76 49 42 95 Cancer pain 75 37 24 75 Anxiety 57 70 73 85 PTSD 42 82 76 95 Autism 68 54 80 77 Depression 76 71 67 83 Migraine/headache 74 44 40 84 Irritable bowel syndrome 62 45 42 85 Parkinson's disease 59 52 43 89 SOURCES: 1. As measured using the validated DASS-21 assessment tool 2. As measured using the validated Insomnia Severity Index (ISI) tool CLINICAL IMPACT EXAMPLE: Our Cannabinoid-Based Care Model Can Improve Symptoms Of Psychological Distress Across A Range Of Diagnoses Emyria 2023 19 OUR ADVANTAGES | ROBUST DATA CAPTURE & ANALYSIS CAPABILITIES We are experienced in tracking clinical outcomes & personalising care CLINICAL IMPACT EXAMPLE: OUR CANNABINOID-BASED CARE MODEL CAN REDUCE OPIOID USE 1 SOURCES: 1. See ASX release 18 Jun 2021 Emyria 2023 20 OUR ADVANTAGES | ACTIVE DRUG DEVELOPMENT & DISCOVERY Our data has inspired multiple drug development & registration programs EMD-RX5 EMD-MX1 EMD-RX7 EMD-RX9 EMD-MX1 EMD-MX1 An Ultra-Pure CBD capsule for over-the-counter treatment of anxiety and stress symptoms. High bioavailability Ultra-Pure CBD for prescription indications, like opioid-sparing. High potency, high bioavailability Ultra-Pure CBD for prescription indications. 5 15% of all adults. 1 Opioid use disorder is a $471.0 billion expense in the US. 3 Market leader: Epidiolex ($1B/yr) 6 In Phase 3 clinical trials. In preclinical screening in USA. Commercialised to Aspen Pharmacare Australia. 2 Preparing for Phase 1 clinical trials. Seeking commercialisation partners. Currently being assessed by the NIH (USA) in their Preclinical Screening Program for Pain (PSPP) program. 4 SOURCES: 1. Australian Institute of Health and Welfare 2018. Australia’s health 2018. Australia’s health series no. 16. AUS 221. 2. See ASX release 04 April 2023 3. https://www.cdc.gov/injury/features/health-econ-cost-of-injury/index.html 4. See ASX release 28 Nov 2022 5. See ASX release 24 April 2023 6.https://investor.jazzpharma.com/news-releases/news-release-details/jaz z-pharmaceuticals-announces-full-year-and-fourth-quarter-2022 Emyria 2023 21 Emyria is now poised to do the same for psychedelic-assisted therapies… OUR CLINICAL SERVICE EVOLUTION Emyria commences drug development programs: novel Ultra-Pure CBD formulation + proprietary MDMA analogues 3 THC & CBD legalised medicines in Australia 1 MDMA & psilocybin legalised medicines in Australia 5 Dec 2016 2018 July 2020 2021 2023 ASX Emyria establishes specialist clinics (Emerald Clinics) and treats first patients with THC and CBD Emyria receives backing from Tenmile 4 Emyria acquires & (~10,000 patients treated since 2) Start of relationship with to explore possibilities for MDMA-assisted therapies SOURCES: 1. https://www.tga.gov.au/news/news/final-decision-scheduling-cannabis-and-tetrahydrocannabinols-frequently-asked-questions#decision 2. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2804653 3. https://emyria.com/development-programs/ 4. See ASX release 22 Nov 2021 5. https://www.tga.gov.au/products/unapproved-therapeutic-goods/mdma-and-psilocybin Emyria 2023 23 OUR CLINICAL SERVICE EVOLUTION The PAX Centre: Australia’s leading complex psychological trauma treatment 1 July 2023 ● Psychiatrist-led service for complex trauma care 1 ● Diverse service offering ● 19 clinicians: psychiatrists, mental health nurses, psychologists, counsellors, OTs & social workers, physical therapists ● Ethics-approved psychedelic assisted therapy model 2 SOURCES: 1. See ASX release 03 Jul 2023 2. See ASX release 08 Jun 2023 Emyria 2023 24 OUR CLINICAL SERVICE TRANSFORMATION Integrated data-centric Primary & Specialist Care providing advanced therapies to patients in need to deliver great patient outcomes, robust data & sustainable revenues Emerald Cli ● Physical & mental health care ~10,000+ patients 4,000+ patients And growing And growing ● Best-in-class conventional care ● + Emerging treatments ○ Cannabinoid-based medicines ○ MDMA-assisted therapies ○ Psilocybin-assisted therapies ○ TMS, Ketamine ● Exceptional Real-World Data collection ● Innovative therapy development ● Sustainable revenues Emyria 2023 25 OUR DELIVERY ADVANTAGE | DATA DRIVEN, MULTIDISCIPLINARY CARE EMYRIA ADVANTAGES SERVICE MODEL KEY STRENGTHS KEY LIMITATIONS GP Clinics Accessible, generalised care Limited support; not specialised ✓ Our model provides specialised care with robust support Specialists High-level, specialised care Often do not address physical health ✓ Our model offers multidisciplinary care covering mental & physical health Specialised service Referral risk for clinicians. “Where do my patients go if treatment fails?” ✓ Our model offers a suite of services before, during & after care Academic & Research Centers Cutting-edge research and treatments Not focused on scalable, cost effective delivery ✓ Our model combines innovative approaches with scalability and cost effective delivery Multidisciplinary, data-driven, scalable ✓ EMYRIA MODEL --- Outperforms other models by delivering comprehensive, data-driven care at scale; + next-generation therapy development “Single service” clinics (eg. “Ketamine Clinics”) Emyria 2023 26 OUR CARE MODEL | A PERSONALISED PATH TO MENTAL WELLNESS We offer a suite of solutions & ongoing support, not just a single service ACTIVE ASSESSMENT, DATA COLLECTION & REVIEW Neuropsychiatric disorders share an overlapping imprint of poor body health 1 which is why Emyria’s care models prioritise both physical and mental well-being. By providing comprehensive care we can achieve and measure exceptional health outcomes as well as develop new therapies and approaches, including our own. EVIDENCE-BASED CARE Rapid intake and assessment Evidence-based care led by psychiatrists & managed by GPs and specially-trained therapists EMERGING TREATMENTS TMS and / or Cannabinoid Therapy SOURCE: 1. Tian YE, et al Evaluation of Brain-Body Health in Individuals With Common Neuropsychiatric Disorders. JAMA Psychiatry. 2023 Apr 26 CLINICAL TRIALS Psychedelic-assisted Therapy Experimental Treatments Emyria 2023 27 OUR GROWTH ENGINE | PROFITABLE SERVICES & ROYALTIES GP + Psychiatrist-led mental health care We provide comprehensive care for complex neuropsychiatric challenges. ● ● ● National care network 30 specialists, GPs & therapists 14,000+ patients treated so far Emyria 2023 28 OUR GROWTH ENGINE | PROFITABLE SERVICES & ROYALTIES GP + Psychiatrist-led mental health care Emerging therapy delivery We provide comprehensive care for complex neuropsychiatric challenges. ● ● ● National care network 30 specialists, GPs & therapists 14,000+ patients treated so far We facilitate safe access to emerging treatments and collect Real-World Data. ● ● ● Psychedelic-assisted therapies Cannabinoid medicines Brain stimulation Emyria 2023 29 OUR GROWTH ENGINE | PROFITABLE SERVICES & ROYALTIES GP + Psychiatrist-led mental health care We provide comprehensive care for complex neuropsychiatric challenges. ● ● ● National care network 30 specialists, GPs & therapists 14,000+ patients treated so far ● ● ● Emerging therapy delivery Proprietary therapy development We facilitate safe access to emerging treatments and collect Real-World Data. We leverage our Real-World Data to create unique medicines and care models. Psychedelic-assisted therapies Cannabinoid medicines Brain stimulation ● ● ● Innovative care models MDMA-inspired medicines Ultra-Pure CBD medicines Emyria 2023 30 OUR GROWTH ENGINE | PROFITABLE SERVICES & ROYALTIES GP + Psychiatrist-led mental health care We provide comprehensive care for complex neuropsychiatric challenges. ● ● ● National care network 30 specialists, GPs & therapists 14,000+ patients treated so far ● ● ● Emerging therapy delivery Proprietary therapy development We facilitate safe access to emerging treatments and collect Real-World Data. We leverage our Real-World Data to create robust IP, unique medicines and care models. Psychedelic-assisted therapies Cannabinoid medicines Brain stimulation Clinical Service Revenues $5.7M $1.6M FY 2023 FY 2024 pre-acquisition Forecast post-acquisition 1 Future growth powered via synergies with potential for strategic acquisitions ● ● ● Innovative care models MDMA-inspired medicines Ultra-Pure CBD medicines Treatment Royalties In addition, we are creating (See slide 6) opportunities for potential licence revenues from commercialisation partners pending successful registration NOTE: 1. Clinical billings forecasts are comprised of current, unaudited management accounts for both Emerald Clinics and Pax Centre as well as a projected additional clinical service revenue from an historical average growth rate of 20%. Investors are cautioned that past performance is not indicative of future performance. Emyria 2023 31 EMYRIA IS PREPARED & READY | AN ADVANCED DATA PLATFORM Data Mastery Utilising advanced technologies like kkkkkkkk Foundry 1, Emyria efficiently translates clinical insights gathered from patients we treat in order to enhance care & therapy development. Our data has been published in leading journals, like JAMA 2 Palantir Foundry is AI-ready with in-built Large Language Model (LLM) and AI capabilities. 3 SOURCES: 1. 2. See ASX 22 Oct 2021 2. Arkell TR, Downey LA, Hayley AC, Roth S. Assessment of Medical Cannabis and Health-Related Quality of Life. JAMA Netw Open. 2023;6(5):e2312522. doi:10.1001/jamanetworkopen.2023.12522 3. https://www.palantir.com/platforms/aip/ Emyria 2023 32 EMYRIA IS PREPARED & READY | INNOVATIVE THERAPY DEVELOPMENT Therapy Innovation Emyria excels in creating and managing intricate care models, including those for newly rescheduled medicines. Emyria is developing its own deep pipeline of novel therapies. Ultra-Pure Cannabinoids Novel MDMA analogues Emerging psychedelic-assisted therapies Emyria 2023 33 EMYRIA IS PREPARED & READY | A COMPREHENSIVE CLINICAL SERVICE Clinical Services Suite The Pax Acquisition combines best-in-class conventional care for physical & mental health along with emerging treatments. Care support from, GPs, psychiatrists, mental health nurses, counsellors, psychologists, physical therapists, social workers and occupational therapists Gathers exceptional Real-World Data and generates sustainable revenues which, in turn, supports innovative therapy development Emyria 2023 34 COMPREHENSIVE SERVICE CLINICAL SERVICES SUITE Emyria 2023 35 OUR WORLD-CLASS TEAM World-leaders in learning health systems, mental health & therapy development Prof Sir John Tooke FRCP, FMedSci Clinician-researcher Expert in learning health systems Dr Karen Smith MD, PhD, MBA, LLM US-based biopharma executive. Multiple FDA approvals Dr Michael Winlo MBBS(Hons), MBA Entrepreneur, big data, clinical trials and drug development Claire Kullak BSc (Nursing) Trauma-specialist and recognised trainer Tracie Ernenwein BSc, MPH, MHM (Nursing) Clinical trial specialist Real-World Data Dr David Gunn MBBS, FRACGP Cannabinoid expert Substance abuse & mental health treatment Mary-Ann Rennie BSc, BCom Business Development Clinics Management GMP manufacturing Dr Stewart Washer PhD (Microbiology) Serial entrepreneur Multiple ASX listings Dr Jon Laugharne MBBS, FRCP (UK), FRANZCP Consultant psychiatrist & therapist Prof Matt Piggott BSc, PhD (Chemistry) Specialist in amphetamine chemistry and novel drug design Dr Jenny Morgan MBBS, FRANZCA Consultant pain specialist C/Prof Alistair Vickery MBBS, FRACGP, FCHSM Medical Director Epidemiological researcher Matt Callahan LLB Patents and litigation Multiple FDA approvals Prof Mat-Martin Iverson Professor, BSc Alta., PhD Br.Col. Neuropharmacologist Oxytocin expert Emyria 2023 36 OUR MAJOR ACHIEVEMENTS & NEAR-TERM CATALYSTS 1st patient dosed for MDMA Emyria commences preclinical screening on MDMA analogues. 5 2022 Psilocybin-assisted therapy care model MDMA & psilocybin legalised medicines in Australia 7 Feb July Rest of 2023 2023 2023 Clinical service growth Payer engagement EMD-RX5 trial finishes Emyria starts Phase 3 clinical trial & announces first commercial partner for first CBD asset 6 Emyria acquires leading trauma centre & treats first patients with MDMA and psilocybin. EMD-RX7/9 development Lead series identified for MDMA-analogue program SOURCES: 1. https://www.tga.gov.au/news/news/final-decision-scheduling-cannabis-and-tetrahydrocannabinols-frequently-asked-questions#decision 2. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2804653 3. https://emyria.com/development-programs/ 4. See ASX release 22 Nov 2021 5. See ASX release 18 Oct 2023 Emyria 2023 6. See ASX release 04 April 2023 7. https://www.tga.gov.au/products/unapproved-therapeutic-goods/mdma-and-psilocybin 37 INVEST IN THE FUTURE OF MENTAL HEALTH WITH EMYRIA (ASX: EMD) A Unique Opportunity in Psychedelic-assisted Therapy ● Uniquely Positioned: Based in Australia - where groundbreaking regulatory changes in mental health treatment are occurring - Emyria stands at the forefront of the psychedelic-assisted therapy revolution with a model can expand globally: An approved treatment protocol; A team of trained therapists; A secured MDMA drug supply; A facility tailored to these therapies; and An established data collection and reporting infrastructure that is AI-ready with Palantir’s Foundry facilitating vital insights into treatment efficacy and patient care innovation ● Proven Track Record: Our extensive experience with unregistered treatments, mastery of data-driven patient care, and recent acquisition of The Pax Centre solidifies our industry leadership ● Together, Emyria and The Pax Centre aim to make history as the first, integrated service to offer psychedelic-assisted therapy in a community practice - care before, during & after treatment while creating strong revenues & generating valuable clinical data ● Multiple therapy development programs, across Ultra-Pure cannabinoids, MDMA-analogues and psychedelic-assisted therapies - each with large patient populations and market potential Emyria 2023 38 CONTACT INFORMATION Michael Winlo Investors Media General mwinlo@emyria.com investors@emyria.com media@emyria.com info@emyria.com INVESTOR HUB: https://investorhub.emyria.com/ APPENDIX: Emyria 2023 40 COMPARE TWO PATIENT JOURNEYS TODAY’s EXPERIENCE: GP attempts to refer Sally to a mental health clinician… …with 1 in 3 80% of patients do …however, the treatment is not effective. antidepressants, neither does Sally. Psychiatrist considers emerging therapies but is unsure where to refer… Sally is now unsure where to go next? Her GP? Her psychiatrist? ED?.... not respond to providers closed to new appointments, multiple attempts required. ? After a waitlist Sally is Books appointment with GP. started on medication. Sally is seeking care for mental health symptoms Books appointment with the Emyria team. Sally is contacted within 24 EMYRIA’S MODEL …eventually, Sally is referred to treatment center providing a single emerging therapy… 6 month hours. Receives a rapid & comprehensive evaluation. Enrolled in a multidisciplinary care program supported by specialists, GPs & allied health clinicians addressing physical & mental well being By remaining in the care model, Sally is regularly reviewed and, if appropriate, provided options like access emerging therapies or adjacent programs to reach her health goals Clinical data generated supports innovative treatment development Emyria 2023 41 OUR CARE LANDSCAPE | NEUROPSYCHIATRIC DISORDERS We are focussed on Five Major global physical & mental health conditions: Complex Trauma Depression Anxiety Chronic Pain Parkinson’s Disease 3.6% of US adults USD$70 billion 1 8.4% of US adults USD$210 billion 2 19.1% of US adults USD$42 billion 3 11.2% of US adults USD$635 billion 4 ~1M US adults USD$51.9 billion 5 SOURCES: 1. https://www.nimh.nih.gov/health/statistics/post-traumatic-stress-disorder-ptsd 2. https://www.nimh.nih.gov/health/statistics/major-depression 3. https://www.nimh.nih.gov/health/statistics/any-anxiety-disorder 4. Rikard SM, et al. Chronic Pain Among Adults — United States, 2019–2021 5. Yang, W., et al. Current and projected future economic burden of Parkinson’s disease in the U.S.. npj Parkinson’s Dis. 6, 15 (2020). https://doi.org/10.1038/s41531-020-0117-1 6. www.phoenixaustralia.org/research/research-publications/ 7. https://www.aihw.gov.au/mental-health/overview/mental-illness 8. National Study of Mental Health and Wellbeing 2020-21 series, Australian Bureau of Statistics 9. https://shakeitup.org.au/understanding-parkinsons 10. https://www.aihw.gov.au/mental-health Emyria 2023 42 OUR INNOVATIVE THERAPY PIPELINE Harnessing Real-World Data to develop impactful therapies PROGRAM DEVELOPMENT GOAL STAGE COMMERCIAL STATUS CATEGORY LEADER Ultra-Pure CBD capsules | Highly bioavailable CBD EMD-RX5 Pharmacy treatment for mild anxiety & stress Active Phase 3 clinical trials Partnered with ASPEN PHARMACARE AUSTRALIA 1 N/A EMD-RX